Jump to section
To reimagine clinical trials and deliver faster and more efficient trials for sponsors.
Few candidates hear
back within 2 weeks
10% employee growth in 12 months
Clinical trials can decide the financial success for a drug that takes decades to make, as without them the Food and Drug Administration cannot approve it. Vial organizes the trial process, offering three technology platforms for starting up sites, capturing data and recruiting patients.
The problem currently faced by the biotech industry is that clinical trials are slow-moving and capital-intensive. One inefficiency is the specificity required when cherry-picking the right candidates for a drug. Aiding this process, Vial helps companies find patients across any given country and better collect data that can be organized.
With impressive funding at its disposal, one round recently led by General Catalyst, Vial will continue to help simplify an unorganised industry. With investments in this field becoming increasingly active, Vial is well placed to continue its upwards growth.
Freddie
Company Specialist at Welcome to the Jungle
Dec 2022
$67m
SERIES B
This company has top investors
Andrew Brackin
(Co-founder)Previously served as CRO for Vial. Experience as Early Head of Growth for Newfront and as part of the Founding Team for Jobr for Business.
Simon Burns
(CEO & co-founder)Previously acted as Senior Product Manager for Chime and as Product Manager for Opendoor. Co-founded Wealthcoin.
Operations & Strategy
Product
Design